Pacira BioSciences (PCRX) Interest Expenses (2010 - 2026)

Pacira BioSciences' Interest Expenses history runs 17 years deep, the most recent figure standing at $57.3 million for Q1 2026.

• On a quarterly basis, Interest Expenses changed 0.0% year-over-year to $57.3 million in Q1 2026; TTM through Mar 2026 was $57.3 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $57.3 million, up 130.9% from the prior year.
• Interest Expenses rose to $57.3 million in Q1 2026 per PCRX's latest filing, from $4.8 million in the prior quarter.
• Across five years, Interest Expenses topped out at $60.2 million in Q2 2025 and bottomed at $2.7 million in Q4 2023.
• The 5-year median for Interest Expenses is $10.2 million (2022), against an average of $27.8 million.
• Across the five-year window, Interest Expenses slumped 83.64% in 2022 and surged 1550.82% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $4.4 million in 2022, then slumped by 37.98% to $2.7 million in 2023, then surged by 31.58% to $3.6 million in 2024, then surged by 36.17% to $4.8 million in 2025, then jumped by 1082.66% to $57.3 million in 2026.
• Per Business Quant, the three latest PCRX Interest Expenses figures stand at $57.3 million (Q1 2026), $4.8 million (Q4 2025), and $57.3 million (Q3 2025).